Advertisement
Advertisement
Edesa Biotech and InflaRx: Advancing ARDS Treatment with Vilobelimab
PremiumCompany AnnouncementsEdesa Biotech and InflaRx: Advancing ARDS Treatment with Vilobelimab
18d ago
JUST BREATHE: A New Hope for ARDS Treatment and Market Impact
Premium
Company Announcements
JUST BREATHE: A New Hope for ARDS Treatment and Market Impact
18d ago
Edesa Biotech Amends Agreement with Canadian Government
Premium
Company Announcements
Edesa Biotech Amends Agreement with Canadian Government
1M ago
Edesa Biotech’s ARDS Study: A Breath of Fresh Air for Investors?
PremiumCompany AnnouncementsEdesa Biotech’s ARDS Study: A Breath of Fresh Air for Investors?
4M ago
Edesa Biotech Advances ARDS Treatment with JUST BREATHE Study
Premium
Company Announcements
Edesa Biotech Advances ARDS Treatment with JUST BREATHE Study
4M ago
Edesa Biotech’s ARDS Trial: A Breath of Fresh Air for Innovative Therapies
Premium
Company Announcements
Edesa Biotech’s ARDS Trial: A Breath of Fresh Air for Innovative Therapies
4M ago
Edesa Biotech initiated with a Buy at Lucid Capital
PremiumThe FlyEdesa Biotech initiated with a Buy at Lucid Capital
6M ago
Edesa Biotech Shifts Focus to Vitiligo Treatment in Q2 2025
Premium
Company Announcements
Edesa Biotech Shifts Focus to Vitiligo Treatment in Q2 2025
6M ago
Is EDSA a Buy, Before Earnings?
Premium
Pre-Earnings
Is EDSA a Buy, Before Earnings?
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100